期刊文献+

A Biobank for Long-term and Sustainable Research in the Field of Congenital Heart Disease in Germany

A Biobank for Long-term and Sustainable Research in the Field of Congenital Heart Disease in Germany
原文传递
导出
摘要 Congenital heart disease (CHD) is the most fi'equent birth defect (0.8% 1% of all live births). Due to the advance in prenatal and postnatal early diagnosis and treatment, more than 90% of these patients survive into adulthood today. However, several mid- and long-term morbidi- ties are dominating the follow-up of these patients. Due to the rarity and heterogeneity of the phenotypes of CHD, multicenter registry-based studies are required. The CHD-Biobank was established in 2009 with the aim to collect DNA from patients and their parents (trios) or fi'om affected families, as well as cardiovascular tissues from patients undergoing corrective heart surgery for cardiovascular malformations. Clinical/phenotype data are matched to the International Paediatric and Congenital Cardiac Code (IPCCC) and the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). The DNA collection currently comprises samples from approximately 4200 participants with a wide range of CHD phenotypes. The collection covers about 430 trios and 120 families with more than one affected member. The cardiac tissue collection comprises 1143 tissue samples [Yore 556 patients alter open heart surgery. The CHD-Biobank provides a comprehensive basis for research in the field of CHD with high standards of data privacy, IT management, and sample logistics. Congenital heart disease (CHD) is the most fi'equent birth defect (0.8% 1% of all live births). Due to the advance in prenatal and postnatal early diagnosis and treatment, more than 90% of these patients survive into adulthood today. However, several mid- and long-term morbidi- ties are dominating the follow-up of these patients. Due to the rarity and heterogeneity of the phenotypes of CHD, multicenter registry-based studies are required. The CHD-Biobank was established in 2009 with the aim to collect DNA from patients and their parents (trios) or fi'om affected families, as well as cardiovascular tissues from patients undergoing corrective heart surgery for cardiovascular malformations. Clinical/phenotype data are matched to the International Paediatric and Congenital Cardiac Code (IPCCC) and the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). The DNA collection currently comprises samples from approximately 4200 participants with a wide range of CHD phenotypes. The collection covers about 430 trios and 120 families with more than one affected member. The cardiac tissue collection comprises 1143 tissue samples [Yore 556 patients alter open heart surgery. The CHD-Biobank provides a comprehensive basis for research in the field of CHD with high standards of data privacy, IT management, and sample logistics.
出处 《Genomics, Proteomics & Bioinformatics》 SCIE CAS CSCD 2016年第4期181-190,共10页 基因组蛋白质组与生物信息学报(英文版)
基金 supported by the Competence Network for Congenital Heart Defects which is funded by the Federal Ministry of Education and Research of Germany (BMBF Grant No. 01GI0601) until 2014 supported by the DZHK (German Centre for Cardiovascular Research) (as of 2015)
关键词 Congenital heart defects Multi-center research BIOREPOSITORY Genetic research DNA Congenital heart defects Multi-center research Biorepository Genetic research DNA
  • 相关文献

参考文献27

  • 1Bansal V, Dorn C, Grunert M, Klaassen S, Hetzer R, Berger F, et aL Outlier-based identification of copy number variations using targeted resequencing in a small cohort of patients with tetralogy of FaUot. PLoS One 2014;9:e85375.
  • 2A1 TurkJ S, Manickaraj AK, Mercer CL, Gerety S, Hitz MP, Lindsay S, et al. Rare variants in NR2F2 cause congenital heart defects in humans. Am J Hum Genet 2014;94:574-85.
  • 3Moosmann J, Uebe S, Dittrich S, Rfiffer A, Ekici AB, Toka O. Novel loci for non.syndromic ~oarctation of the aorta in sporadic and familial cases. PLoS One 2015;10:e0126873.
  • 4Arndt AK, Schafer S, Drenckhahn JD. Sabeh MK, Plovie ER. Caliebe A, et al. Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. Am J Hum Genet 2013;93:67-77.
  • 5Hoffman Jl, Kaplan S. The incidence of congenital heart disease. J Am Coil Cardiol 2002:39:1890- 900.
  • 6Schwedler G, Lindinger A, Lange PE, Sax U, Olchvary J, Peters B, et al. Frequency and spectrum of congenital heart defects among live births in Gernmny: a study of the competence network for congenital heart defects. Clin Res Cardiol 2011:100:1111-7.
  • 7Marelli A J, Mackie AS, lonescu-lttu R, Rahrne E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007;115:163-7.
  • 8Kovacs AH, Verstappen A. The whole adult congenital heart disease patient. Prog Cardiovasc Dis 2011,53:247-53.
  • 9Sable C, Foster E, Uzark K, Bjornsen K, Canobbio MM, Connolly HM, et al. Best practices in managing Iransition to adulthood for adolescents with congenital heart disease: the transition process and medical and psychosocial issues: a scientific statement from the American Heart Association. Circulation 2011;123:1454-85.
  • 10Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. Circulation 2010;122:2264-72.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部